William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating on October 22.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising potential of Beam Therapeutics’ BEAM-101 in treating sickle cell disease. The updated data from the BEACON trial, presented at the American Society of Hematology conference, demonstrates robust efficacy with significant induction of fetal hemoglobin and recovery of total hemoglobin levels. The trial results show no vaso-occlusive crises post-engraftment, which is a significant positive outcome for patients.
Moreover, the safety profile of BEAM-101 remains consistent, with no severe adverse events reported, and favorable manufacturing and engraftment dynamics further support the therapeutic’s potential. The majority of patients required only a single mobilization cycle, and engraftment times were within expected ranges, indicating efficient treatment processes. These factors collectively reinforce the clinical and operational differentiation of BEAM-101, justifying the Buy rating by Sami Corwin.
In another report released on October 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.